Pharmacokinetics, safety and tolerability, and efficacy of hyaluronidase-facilitated subcutaneous immunoglobulin 10% (HyQvia®) in Japanese patients with primary immunodeficiency diseases

This phase 3 open-label study (jRCT2031210457; NCT05150340; January 2022–August 2023) evaluated pharmacokinetics, safety and tolerability, and efficacy of recombinant hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) 10% in Japanese patients with primary immunodeficiency diseases (PID) t...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Hirokazu Kanegane, Masataka Ishimura, Eisuke Suganuma, Tomoyuki Imagawa, Takayuki Hoshina, Tomoki Kawai, Hidenori Ohnishi, Satoshi Okada, Chihiro Suzuki, Kentarou Kudou, Sharon Russo-Schwarzbaum, Immanuel Freedman, Barbara McCoy, Zhaoyang Li, Atsushi Kuga
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Taylor & Francis Group 2026-02-01
Schriftenreihe:	Immunological Medicine
Schlagworte:	MeSH terms: immunoglobulins pharmacokinetics primary immunodeficiency diseases Facilitated subcutaneous immunoglobulin recombinant hyaluronidase inborn errors of immunity
Online-Zugang:	https://www.tandfonline.com/doi/10.1080/25785826.2025.2607878
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!